Lably
Skip to content

Cholera toxin

Bacteria-produced protein complex and disease agent

  • 10 min read
  • 5 chapters

Related on Lably

Through Pathogen, Globalization and Water pollution

History

The production of cholera toxin by Vibrio cholerae is the pathogenic agent of the ancient disease cholera, originally found in Asia and Europe. The first modern global pandemic emerged in the Ganges Delta in 1817. Globalization that was developing in the nineteenth century spread it worldwide through the course of seven subsequent pandemics. When cholera arrived in London in 1832, its transmission was poorly understood, with many blaming miasma. A physician, John Snow (1813–1858), was an advocate of water contamination as the cause of its spread—famously ending an outbreak by removing a public water pump handle in central London. His theory however only gained acceptance years after his death, through the discovery of the cholera bacterium.

Discovery and isolation

The discovery of the cholera toxin has widely been accredited to Robert Koch, a physician and microbiologist. In 1886, Koch hypothesised that Vibrio cholerae produced a substance that caused cholera symptoms. Isolation of the bacteria had already been conducted 30 years earlier by Italian anatomist Filippo Pacini, who had subsequently published his work in his native language.

In 1951, Sambhu Nath De confirmed Koch's hypothesis, through De's research that involved injecting heat-killed V. cholerae into rabbits. From this experiment he determined that an endotoxin is released as the bacteria disintegrate, and that this endotoxin is responsible for the disease symptoms. Then, in 1959, De performed a follow-up experiment, injecting bacteria-free culture filtrate of V. cholerae into the rabbit's small intestine and thereby proving the existence of the toxin by the fluid accumulation.

Purification and mechanism

The next decade saw Richard Finkelstein's research team successfully isolate and purify the cholera toxin (CT). This research identified the holotoxin (AB5) as the primary active agent, whereas the B5 oligomer lacked intrinsic toxicity but played a key role in triggering cholera symptoms. Subsequent biochemical methods confirmed the complex subunit structure of the toxin, leading to comprehensive understanding of its mechanisms.

Another significant landmark occurred in 1973 when King and van Heyningen identified the GM1 ganglioside as the CT receptor. Their experiments revealed that GM1 blocked the toxin's ability to enhance capillary permeability in rabbit skin, preventing fluid accumulation in ligated rabbit intestinal loops. Additionally, they discovered that the receptor obstructed its effect on the adenylyl cyclase pathway in guinea pig intestinal tissue. These findings would come to aid in future pursuits of medical applications of the toxin, through increasingly detailed knowledge of its effects.

Modern relevance

Modern sanitation facilities have almost completely removed cholera from industrialized nations, in contrast to economically-disadvantaged regions where the disease claims over 100,000 annual deaths. The disease primarily targets people who live in areas with inadequate water sanitation, ongoing conflicts, and restricted healthcare access. A prominent example is the 2010 Haiti earthquake, which caused the worst cholera epidemic in 25 years, after a 10-month lag period.

There are over 200 recorded serogroups of V. cholerae, of which only serogroups O1 and O139 lead to epidemic sickness, whereas serotypes that cause sporadic outbreaks are termed non-O1/non-O139 V. cholerae. Serogroup O1 has two distinct strains, namely El Tor and Classical, and has been the reason for all seven pandemics. El Tor (strain16961) extensively replaced the Classical strain during the start of the seventh pandemic in the 1960s. Serogroup O139 appeared in 1992, and remains prevalent as of 2015.

Clinical and public health impact

Cholera becomes fatal within hours when left untreated. The World Health Organization reported more than 730,000 cases and 5,100 deaths in 33 countries from January through November 2024. Increased vaccine production has not solved an ongoing shortage of oral cholera vaccines, which hampers preventive vaccination programs. Research indicates that endemic countries experience 2.9 million cholera cases, but official records probably underestimate the actual number of cases. The numbers demonstrate the toxin's dual role in making cholera both a critical medical condition and a significant public health concern.

Sign in to keep reading

4 more chapters are free with a Lably account.

More in Biology